Designing Pharmacogenomic Studies to be Fit for Purpose
Authors:
- 13 December 2010
- journal article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 11 (12) , 1657-1667
Abstract
The 2010 US FDA-Drug Industry Association (DIA) Pharmacogenomics Workshop, the fifth in a series of meetings that begun in 2002, brought together multidisciplinary experts from regulatory authorities, medical research, healthcare and drug development. This article summarizes the 'Designing Pharmacogenomic Studies to be Fit for Purpose' track in which considerations regarding the use of retrospective and prospective studies were examined in relation to their ability to influence treatment decisions and labeling for drugs. The aim of the session, using real-world examples (KRAS/panitumumab and HLA-B*5701/abacavir), was to identify good scientific principles that would guide the design of studies to identify subgroups of responders during development programs (including marketed drugs), which could subsequently be used to guide treatment decisions.Keywords
Funding Information
- GlaxoSmithKline
- Pfizer Inc
This publication has 30 references indexed in Scilit:
- Statistical considerations in evaluating pharmacogenomics-based clinical effect for confirmatory trialsClinical Trials, 2010
- A comparability study of 5 commercial KRAS testsDiagnostic Pathology, 2010
- Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab AloneClinical Colorectal Cancer, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With CetuximabJournal of Clinical Oncology, 2007
- Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapyBritish Journal of Cancer, 2007
- Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody TherapiesCancer Research, 2007
- Association of k-ras, b-raf, and p53 Status With the Treatment Effect of BevacizumabJNCI: Journal of the National Cancer Institute, 2005
- RAS oncogenes: the first 30 yearsNature Reviews Cancer, 2003
- Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ studyBritish Journal of Cancer, 2001